| PAVELKA, K., J. GATTEROVA, D. TEGZOVA, K. JAROSOVA, J.T. STUDYNKOVA, Adam SVOBODNÍK, J. SVIHALEK, Ladislav DUŠEK and J. VENCOVSKY. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment. Clinical and Experimental Rheumatology. 2007, vol. 25, No 4, p. 540-545, 5 pp. ISSN 0392-856X. |
Other formats:
BibTeX
LaTeX
RIS
@article{753543,
author = {Pavelka, K. and Gatterova, J. and Tegzova, D. and Jarosova, K. and Studynkova, J.T. and Svobodník, Adam and Svihalek, J. and Dušek, Ladislav and Vencovsky, J.},
article_number = {4},
keywords = {rheumatoid arthritis; biological treatment; radiographic progression},
language = {eng},
issn = {0392-856X},
journal = {Clinical and Experimental Rheumatology},
title = {Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment},
volume = {25},
year = {2007}
}
TY - JOUR
ID - 753543
AU - Pavelka, K. - Gatterova, J. - Tegzova, D. - Jarosova, K. - Studynkova, J.T. - Svobodník, Adam - Svihalek, J. - Dušek, Ladislav - Vencovsky, J.
PY - 2007
TI - Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
JF - Clinical and Experimental Rheumatology
VL - 25
IS - 4
SP - 540-545
EP - 540-545
SN - 0392856X
KW - rheumatoid arthritis
KW - biological treatment
KW - radiographic progression
N2 - Objective To evaluate the clinical status and radiographic progression in patients with rheamzatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. Methods Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. Results Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.9 before the initiation of treatment (p = 0.011). Conclusion Data derived from the Czech National Registry, which reflect general clinical practice, show a significant retardation of radiographic progression in patients treated with anti-TNF and the magnitude of the improvement seen is similar to results from clinical trials
ER -
PAVELKA, K., J. GATTEROVA, D. TEGZOVA, K. JAROSOVA, J.T. STUDYNKOVA, Adam SVOBODNÍK, J. SVIHALEK, Ladislav DUŠEK and J. VENCOVSKY. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment. \textit{Clinical and Experimental Rheumatology}. 2007, vol.~25, No~4, p.~540-545, 5 pp. ISSN~0392-856X.
|
